Posts Tagged ‘af’

Relationships between anticoagulation regimen, risk score and adverse outcomes in dialysis patients with atrial fibrillation

Atrial fibrillation (AF) is the commonest cardiac arrhythmia including in end-stage renal failure patients, and there is increasing evidence that anticoagulation leads to more harm than benefit in these patients on dialysis. We reviewed the characteristics, management and outcomes of end-stage renal failure patients in dialysis with AF with a focus on warfarin anticoagulation and risk scores.

T. Wang, J. Sathananthan, C. Hood, G. Gamble, M. Marshall, A. Kerr
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

AV junction ablation audit – Auckland City Hospital

Atrio-ventricular junction (AVJ) ablation remains a strategy for patients with symptomatic atrial fibrillation (AF). We evaluated demographics and procedural outcomes in a contemporary series of patients undergoing AVJ ablation at our institution.

J. Voss, L. Maher, C. Jones, N. Lever
Auckland City Hospital, Auckland
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

The Australian experience of government subsidisation of novel oral anticoagulants (NOACs) Online Only

NOACs offer physicians an alternative to warfarin for stroke prevention in atrial fibrillation (AF). The Pharmaceutical Benefits Scheme (PBS) is the system whereby the Australian Government subsidises medications for defined indications. Initially NOACs were only subsidised for specific venous thromboembolism treatment and prevention indications. Authorities to prescribe NOACs for prevention of stroke in at-risk patients with AF were added to the PBS in August 2013 for rivaroxaban, and September 2013 for apixaban and dabigatran.

A. Vlachadis Castles, W. van Gaal
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.

Interested in joining CSANZ?